Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Sponsor: Samsung Bioepis Co., Ltd.
Summary
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Official title: A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
149
Start Date
2026-03-23
Completion Date
2030-07
Last Updated
2026-05-11
Healthy Volunteers
No
Conditions
Interventions
E303
All participants will receive an intravenous (IV) infusion of E303
Locations (3)
Research Site
Scottsdale, Arizona, United States
Research Site
Fairfax, Virginia, United States
Research Site
Adelaide, Australia